keyword
MENU ▼
Read by QxMD icon Read
search

RPLND for testicular cancer

keyword
https://www.readbyqxmd.com/read/27879966/andrological-complications-following-retroperitoneal-lymphnode-dissection-for-testicular-cancer-a-narrative-review
#1
Alessandro Crestani, Francesco Esperto, Marta Rossanese, Gianluca Giannarini, Nicola Nicolai, Vincenzo Ficarra
Retroperitoneal lymphnode dissection (RPLND) is a fundamental surgical step in the treatment of testicular cancer. Nowadays primary RPLND has partially lost its role in favour of active surveillance (for low risk stage I disease) and short cycle chemotherapy in non-seminomatous germ cell tumour (NSGCT). Conversely, postchemotherapy-RPLND (PC-RPLND) remains the standard treatment for residual masses after chemotherapy. In consideration of curability rate of testicular cancer and the life expectancy of testicular cancer survivors the identification and the prevention of andrological complications became fundamental...
November 23, 2016: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/27859263/post-chemotherapy-retroperitoneal-teratoma-in-nonseminomatous-germ-cell-tumors-do-predictive-factors-exist-results-from-a-national-multicenter-study
#2
Marie Dusaud, Bernard Malavaud, Younes Bayoud, Philippe Sebe, Jean Luc Hoepffner, Laurent Salomon, Alain Houlgatte, Géraldine Pignot, Jérome Rigaud, Aude Fléchon, Christian Pfister, Morgan Rouprêt, Michel Soulié, Arnaud Méjean, Xavier Durand
BACKGROUND AND OBJECTIVES: To identify predictive preoperative factors of the presence of teratoma in retroperitoneal lymph node dissection specimens. METHODS: We performed a 20 years multicenter retrospective analysis of all patients who underwent retroperitoneal lymph node dissection for residual masses after chemotherapy (PC-RPLND). Patients had undergone PC-RPLND after chemotherapy for advanced testicular cancer. The histologic components of the primary tumor were compared with those of the residual masses using logistic regression...
November 18, 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27831507/surgical-management-of-complex-residual-masses-following-systemic-chemotherapy-for-metastatic-testicular-germ-cell-tumours
#3
A Heidenreich, F Haidl, P Paffenholz, Ch Pape, U Neumann, D Pfister
BACKGROUND: Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumors. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases. PATIENTS AND METHODS: A total of 185 patients underwent PC-RPLND and we identified 25 (13...
November 9, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27618772/management-of-stage-i-testicular-germ-cell-tumours
#4
Michal Chovanec, Nasser Hanna, K Clint Cary, Lawrence Einhorn, Costantine Albany
Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease...
September 13, 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27460844/post-chemotherapy-robotic-bilateral-retroperitoneal-lymph-node-dissection-using-a-novel-single-dock-technique
#5
Thomas E Stout, Samit D Soni, Alvin C Goh
There have been no previous reports of post-chemotherapy robotic bilateral retroperitoneal lymph node dissection (RPLND) using a single-dock technique. One deterrent of robotic RPLND is that accessing bilateral retroperitoneal spaces requires patient reposition and surgical robot redocking, therefore increasing operative time. Herein we provide the first step-by-step description of a single-dock technique for robotic bilateral RPLND in the post-chemotherapy setting. We describe port placement and technique for robot positioning to optimize access to bilateral retroperitoneal spaces with a single dock...
July 26, 2016: Journal of Robotic Surgery
https://www.readbyqxmd.com/read/27372281/utilization-of-retroperitoneal-lymph-node-dissection-for-testicular-cancer-in-the-united-states-results-from-the-national-cancer-database-1998-2011
#6
Cory M Hugen, Brian Hu, Claudio Jeldres, Claire Burton, Craig R Nichols, Christopher R Porter, Siamak Daneshmand
INTRODUCTION: Retroperitoneal lymph node dissection (RPLND) for the treatment of testicular cancer is a relatively rare and complex operation that may contribute to differences in utilization. We sought to characterize the use of RPLND between different categories of cancer center facilities in the United States. MATERIALS AND METHODS: The National Cancer Database was queried for patients with germ cell tumors treated at different types of cancer centers between 1998 and 2011...
June 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27235751/pelvic-lymph-node-dissection-in-patients-treated-for-testis-cancer-the-memorial-sloan-kettering-cancer-center-experience
#7
Shaheen R Alanee, Brett S Carver, Darren R Feldman, Robert J Motzer, George J Bosl, Joel Sheinfeld
OBJECTIVE: To describe the pathologic findings and clinical outcome data for patients undergoing pelvic lymph node dissection (PLND) in the course of management of testicular germ cell tumors at Memorial Sloan Kettering Cancer Center (MSKCC). PATIENTS AND METHODS: Following institutional review board approval, data on 2186 patients who underwent retroperitoneal lymph node dissection (RPLND) at MSKCC between 1989 and 2011 were retrospectively reviewed. Of these 2186 patients, we analyzed data for 44 patients (2%) who underwent PLND at the time of RPLND...
September 2016: Urology
https://www.readbyqxmd.com/read/27234998/safety-and-early-oncologic-effectiveness-of-primary-robotic-retroperitoneal-lymph-node-dissection-for-nonseminomatous-germ-cell-testicular-cancer
#8
Shane M Pearce, Shay Golan, Michael A Gorin, Amy N Luckenbaugh, Stephen B Williams, John F Ward, Jeffrey S Montgomery, Khaled S Hafez, Alon Z Weizer, Phillip M Pierorazio, Mohamad E Allaf, Scott E Eggener
BACKGROUND: Primary robot-assisted retroperitoneal lymph node dissection (R-RPLND) has been studied as an alternative to open RPLND in single-institution series for patients with low-stage nonseminomatous germ cell tumors (NSGCT). OBJECTIVE: To evaluate a multicenter series of primary R-RPLND for low-stage NSGCT. DESIGN, SETTING, AND PARTICIPANTS: Between 2011 and 2015, 47 patients underwent primary R-RPLND at four centers for Clinical Stage (CS) I-IIA NSGCT...
May 24, 2016: European Urology
https://www.readbyqxmd.com/read/27169016/development-of-cns-type-primitive-neuroectodermal-tumor-in-metastatic-testicular-mixed-germ-cell-tumor
#9
Anobel Y Odisho, Joseph T Rabban, Maxwell V Meng
A 29-year-old man presenting with a retroperitoneal mass was found to have a testis lesion consistent with mixed germ cell tumor and the RPLND specimen showed teratoma with an area of central nervous system-type primitive neuroectodermal tumor (PNET) not present in the testis. Whether such primitive tumor components represent a de novo tumor component or represent progression from existing neuroepithelial teratomatous elements is unclear. Given the high likelihood of residual tumor and possibility of malignant transformation, post-chemotherapy RPLND remains vital in treating patients with testis cancer...
May 2016: Urology Case Reports
https://www.readbyqxmd.com/read/27068395/robot-assisted-laparoscopic-retroperitoneal-lymph-node-dissection-for-testicular-cancer-evolution-of-the-technique
#10
Sevan Stepanian, Mayank Patel, James Porter
BACKGROUND: Retroperitoneal lymph node dissection (RPLND) is an accepted staging and treatment option for nonseminomatous germ cell tumor. Robotic surgery offers technical advantages and is being increasingly used in urologic procedures. OBJECTIVE: To determine the feasibility and safety of robotic surgery for RPLND. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of robotic (R)-RPLND performed by a single surgeon from April 2008 to October 2014 using two approaches was performed...
April 5, 2016: European Urology
https://www.readbyqxmd.com/read/26968421/robotic-primary-rplnd-for-stage-i-testicular-cancer-a-review-of-indications-and-outcomes
#11
REVIEW
Heather J Chalfin, Wesley Ludwig, Phillip M Pierorazio, Mohamad E Allaf
Patients diagnosed with stage I non-seminomatous germ cell tumor (NSGCT) face the task of selecting a management strategy. Whereas these options all offer excellent survival, unfortunately, each has drawbacks. Retroperitoneal lymph node dissection (RPLND) is a major operation with low, but significant risks of bleeding, chylous ascites, and retrograde ejaculation. Platinum-based chemotherapy is associated with a number of long-term side effects, not all of which are quantified, but include secondary malignancy and early cardiovascular disease...
May 2016: Current Urology Reports
https://www.readbyqxmd.com/read/26820659/-postchemotherapy-residual-tumour-resection-in-complex-metastatic-sites-of-advanced-testicular-germ-cell-tumours
#12
P Paffenholz, D Pfister, A Heidenreich
INTRODUCTION: Postchemotherapy residual tumour resection (PC-RTR) is an integral part of the multimodal therapy for advanced testicular germ cell tumours. Depending on the extent and localisation of the residual mass, PC-RTR may necessitate a multidisciplinary procedure (which should be planned preoperatively), to resolve even complex situations in an oncologically sound manner, with lower treatment-related morbidity The aim of article is to report on the interdisciplinary management of complex residual masses...
May 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/26620368/quality-of-life-analysis-of-the-german-prospective-multicentre-trial-of-single-cycle-adjuvant-bep-versus-retroperitoneal-lymph-node-dissection-in-clinical-stage-i-nonseminomatous-germ-cell-tumours
#13
RANDOMIZED CONTROLLED TRIAL
Hans-Henning Flechtner, Florian Fischer, Peter Albers, Michael Hartmann, Roswitha Siener
BACKGROUND: The superiority of one course of bleomycin, etoposide, and cisplatin (BEP) over retroperitoneal lymph node dissection (RPLND) as adjuvant treatment in patients with clinical stage I nonseminomatous germ cell tumours (CSI-NSGCT) in terms of recurrence has been shown. However, studies providing validated prospective quality-of-life (QoL) data in patients with CSI-NSGCT treated with only one cycle of BEP are lacking. OBJECTIVE: To examine and compare QoL issues in patients with CSI-NSGCT after adjuvant treatment...
March 2016: European Urology
https://www.readbyqxmd.com/read/26539420/postchemotherapy-retroperitoneal-lymph-node-dissection-in-patients-with-nonseminomatous-testicular-cancer-a-single-center-experiences
#14
Mohamadreza Nowroozi, Mohsen Ayati, Amir Arbab, Hassan Jamshidian, Hamidreza Ghorbani, Hassan Niroomand, Mohsen Taheri Mahmoodi, Erfan Amini, Sohrab Salehi, Hamid Hakima, Farid Fazeli, Saeid Haghdani, Alireza Ghadian
BACKGROUND: Testicular cancer accounts for about 1 - 1.5% of all malignancies in men. Radical orchiectomy is curative in 75% of patients with stage I disease, but advance stage with retroperitoneal lymph node involvement needs chemotherapy. All patients who have residual masses ≥ 1 cm after chemotherapy should undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). OBJECTIVES: Treatment of advanced nonseminomatous testicular cancer is usually a combination of chemotherapy and surgery...
September 2015: Nephro-urology Monthly
https://www.readbyqxmd.com/read/26477833/insurance-status-and-differences-in-treatment-and-survival-of-testicular-cancer-patients
#15
Mohamed H Kamel, Mohammed Elfaramawi, Supriya Jadhav, Ahmed Saafan, Omer A Raheem, Rodney Davis
OBJECTIVE: To explore the relationship between insurance status and differences in treatment and survival of testicular cancer patients. The Surveillance, Epidemiology, and End Results (SEER) database was utilized for this study. MATERIALS AND METHODS: Between 2007 and 2011, 5986 testicular cancer patients were included in the SEER database. Patients were classified into nonseminoma and seminoma groups. We compared mortality rates, metastasis (M+) at diagnosis, and rates of adjuvant treatments between the uninsured (UI) and insured (I) populations...
January 2016: Urology
https://www.readbyqxmd.com/read/26371446/outcomes-of-postchemotherapy-retroperitoneal-lymph-node-dissection-following-high-dose-chemotherapy-with-stem-cell-transplantation
#16
Clint Cary, Jose A Pedrosa, Joseph Jacob, Stephen D W Beck, Kevin R Rice, Lawrence H Einhorn, Richard S Foster
BACKGROUND: Characterizing the role of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) after high-dose chemotherapy (HDCT) has been limited by small sample sizes. This study reports on survival after HDCT with stem cell support and PC-RPLND as well as histologic findings in the retroperitoneum. METHODS: The prospectively maintained testicular cancer database of Indiana University was queried for patients receiving HDCT with stem cell transplantation before PC-RPLND...
December 15, 2015: Cancer
https://www.readbyqxmd.com/read/26351740/robot-assisted-retroperitoneal-lymph-node-dissection-in-testicular-cancer
#17
REVIEW
Haidar M Abdul-Muhsin, James O L'esperance, Kimberly Fischer, Michael E Woods, James R Porter, Erik P Castle
Robotic surgical techniques are now being applied in the setting of retroperitoneal lymphadenectomy (RPLND) for testicular cancer. While laparoscopic RPLND has not been widely accepted, reports of robot assisted RPLND (RARPLND) are emerging. This manuscript will review the application of RPLND for testicular cancer, evolution of minimally invasive techniques, the controversies, and current status of RARPLND.
December 2015: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/26268684/sexual-dysfunction-in-testicular-cancer-patients-subjected-to-post-chemotherapy-retroperitoneal-lymph-node-dissection-a-focus-beyond-ejaculation-disorders
#18
K Dimitropoulos, A Karatzas, C Papandreou, D Daliani, I Zachos, L L Pisters, V Tzortzis
Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) represents an integral part of multidisciplinary treatment of advanced germ cell cancer; however, it is associated with a high complications rate. The present study aimed to describe sexual disorders in 53 patients with testicular cancer who underwent full bilateral, non-nerve-sparing PC-RPLND in our institution, focusing beyond ejaculatory dysfunction. The International Index for Erectile Function (IIEF) questionnaire was used as diagnostic tool of male sexual functioning pre-operatively and three months after RPLND, while post-operatively patients were asked to describe and evaluate changes in selected sexual parameters...
May 2016: Andrologia
https://www.readbyqxmd.com/read/25921130/comparative-effectiveness-of-risk-adapted-surveillance-vs-retroperitoneal-lymph-node-dissection-in-clinical-stage-i-nonseminomatous-germ-cell-testicular-cancer-a-retrospective-follow-up-study-of-81-patients
#19
COMPARATIVE STUDY
Gang Fan, Lin Zhang, Lu Yi, Zhi-Qiang Jiang, Yang Ke, Xiao-Shan Wang, Ying-Ying Xiong, Wei-Qin Han, Xiao Zhou, Chun Liu, Xie Yu
PURPOSE: To retrospective assess the potential predictors for relapse and create an effective clinical mode for surveillance after orchidectomy in clinical stage I non-seminomatous germ cell testicular tumors (CSI-NSGCTs). MATERIALS AND METHODS: We analyzed data for CSI-NSGCTs patients with non-lymphatic vascular invasion, %ECa < 50% (percentage of embryonal carcinoma < 50%), and negative or declining tumor markers to their half-life following orchidectomy (defined as low-risk patients); these patients were recruited from four Chinese centers between January 1999 and October 2013...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/25823792/lymph-node-yield-in-primary-retroperitoneal-lymph-node-dissection-for-nonseminoma-germ-cell-tumors
#20
Madhur Nayan, Michael A S Jewett, Joan Sweet, Lynn Anson-Cartwright, Philippe L Bedard, Malcolm Moore, Peter Chung, Padraig Warde, Robert J Hamilton
PURPOSE: The number of lymph nodes removed at surgery for various malignancies has diagnostic and prognostic value. However, there are limited data on the significance of the number of nodes removed at retroperitoneal lymph node dissection performed for testicular nonseminoma germ cell tumors. MATERIALS AND METHODS: From 1979 to 2012 primary open retroperitoneal lymph node dissection was performed by a single experienced surgeon for clinical stage I/II testicular nonseminoma germ cell tumor in 157 patients...
August 2015: Journal of Urology
keyword
keyword
10161
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"